Singapore | HSA Updates Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTPs — Expanding Lifecycle Pharmacovigilance and Safety Reporting Expectations Gallery Singapore | HSA Updates Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTPs — Expanding Lifecycle Pharmacovigilance and Safety Reporting Expectations 2026, April 2026, Members-Only, Moderate Update, Pharmacovigilance, Singapore Singapore | HSA Updates Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTPs — Expanding Lifecycle Pharmacovigilance and Safety Reporting Expectations Please login to view this page. Singapore | HSA Updates Post-Marketing Vigilance Requirements for Therapeutic Products and CTGTPs — Expanding Lifecycle Pharmacovigilance and Safety Reporting Expectationsstuart.mccully2026-05-14T13:59:13+00:00